Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ACLX-002 |
Synonyms | |
Therapy Description |
ACLX-002 is a cell therapy comprising SPRX-002, a soluble protein targeting CD123, and Antigen Receptor Complex T-cells (ARC T-cells), which potentially induces antitumor activity (Cancer Res (2022) 82 (12_Supplement): 587). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ACLX-002 | ACLX 002|ACLX002 | ACLX-002 is a cell therapy comprising SPRX-002, a soluble protein targeting CD123, and Antigen Receptor Complex T-cells (ARC T-cells), which potentially induces antitumor activity (Cancer Res (2022) 82 (12_Supplement): 587). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05457010 | Phase I | ACLX-002 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | Recruiting | USA | 0 |